Barcelona, Spain -- Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort EP") recently attended the Annual Congress of the European Heart Rhythm Association 2023 (EHRA 2023).

MicroPort EP presented the comprehensive EP solutions include Columbus™ 3D EP Navigation System Version3 (“Columbus™ System V3”) and its accompanying FireMagic™TrueForce™ Ablation Catheter (“TrueForce™ Ablation Catheter”), FireMagic™ 3D Irrigatd RF Ablation Catheter, EasyStars™ High Density Mapping Catheter, EasyFinder™ 3D Steerable Diagnostic Catheter, EasyLoop™ Circular Mapping Catheter, PathBuilder™ Transseptal Kit and the new products such as IceMagic™CryoAblation Catheter, etc.

As a Chinese company that is capable of providing comprehensive EP solutions with 3D navigation system, devices and consumables, MicroPort EP attracted experts from Spain, France，Germany, United Kingdom, Belgium, Italy and other countries and regions to experience its products and share their expertise at the booth.

The exhibition’s design adopts the patient-centered user experience mode, visitors can gradually experience and visit different customer experience centers from diagnosis to treatment to patient care, fully demonstrating the advantages of MicroPort EP in providing comprehensive EP solutions. Around 50 experts from different countries experienced the Columbus™ System V3 and commended its stability and smooth while creating the geometry and gave compliment on the real-time sensitivity and precision of TrueForce™ Ablation Catheter. In addition, experts from many countries showed great interest in the comprehensive EP Solutions, expressed their expectations for the upcoming products like EasyStars™ High Density Mapping Catheter, IceMagic™CryoAblation Catheter, and gave valuable suggestions on the electrode spacing and balloon size after studying our products’ performance and characteristics.

To date, MicroPort EP products have been exported to more than 30 countries. In future, MicroPort EP will continue to build a differentiated product portfolio and expand its global reach, offering comprehensive solutions for diagnosis and therapy of EP interventions to more patients and doctors worldwide.